Bristol-Myers Squibb Company

Bristol-Myers Squibb Company
430 E. 29th Street, 14th Floor,
New York, NY 10016
Phone: 1-800-332-2056Website: https://www.bms.com/Careers: www.bms.com/careers/Pages/home.aspxPatient Assistance Program: www.bms.com/products/Pages/programs.aspx

Latest news

U.S. FDA Approves Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
5 April 2024
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
14 March 2024
U.S. Food and Drug Administration Approves Opdivo (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
7 March 2024
FDA Approves Augtyro (repotrectinib) for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
16 November 2023
U.S. Food and Drug Administration Approves Opdivo (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma
13 October 2023
U.S. FDA Approves Bristol Myers Squibb’s Reblozyl (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
28 August 2023
Updated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
16 August 2023
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
30 May 2023
OncoSec presents encouraging early data with TAVO-EP combined with Opdivo in neoadjuvant melanoma
15 November 2022
Bristol Myers Squibb Announces New Sotyktu™ (deucravacitinib) Long-Term Data Showing Clinical Efficacy Maintained for Up to Two Years with Continuous Treatment in Moderate-to-Severe Plaque Psoriasis
10 September 2022

Drugs Associated with Bristol-Myers Squibb Company

Bristol-Myers Squibb Company manufactures, markets and/or distributes more than 33 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.

Brand/Generic Name	Reviews	Rating
Abecma Generic name: idecabtagene vicleucel Drug class: miscellaneous antineoplastics
Abraxane Generic name: paclitaxel protein-bound Drug class: mitotic inhibitors	5 reviews	6.2 / 10
Augtyro Generic name: repotrectinib Drug class: multikinase inhibitors
Azactam Generic name: aztreonam Drug class: miscellaneous antibiotics
Baraclude Generic name: entecavir Drug class: nucleoside reverse transcriptase inhibitors (NRTIs)	1 review	10 / 10
Breyanzi Generic name: lisocabtagene maraleucel Drug class: miscellaneous antineoplastics
Camzyos Generic name: mavacamten Drug class: miscellaneous cardiovascular agents	3 reviews	10 / 10
Droxia Generic name: hydroxyurea Drug class: antimetabolites
Eliquis Generic name: apixaban Drug class: factor Xa inhibitors	196 reviews	5.0 / 10
Empliciti Generic name: elotuzumab Drug class: miscellaneous antineoplastics
Evotaz Generic name: atazanavir/cobicistat Drug class: antiviral combinations
Hydrea Generic name: hydroxyurea Drug class: antimetabolites	8 reviews	7.2 / 10
Idhifa Generic name: enasidenib Drug class: miscellaneous antineoplastics
Inrebic Generic name: fedratinib Drug class: multikinase inhibitors
Istodax Generic name: romidepsin Drug class: histone deacetylase inhibitors	1 review	1.0 / 10
Kenalog-10 Generic name: triamcinolone Drug class: glucocorticoids	20 reviews	7.8 / 10
Kenalog-40 Generic name: triamcinolone Drug class: glucocorticoids	105 reviews	6.2 / 10
Nulojix Generic name: belatacept Drug class: selective immunosuppressants	1 review	10 / 10
Onureg Generic name: azacitidine Drug class: miscellaneous antineoplastics
Opdivo Generic name: nivolumab Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)	75 reviews	5.2 / 10
Opdualag Generic name: nivolumab/relatlimab Drug class: antineoplastic combinations
Orencia Generic name: abatacept Drug class: antirheumatics, selective immunosuppressants	66 reviews	6.0 / 10
Pomalyst Generic name: pomalidomide Drug class: miscellaneous antineoplastics, other immunosuppressants	3 reviews	10 / 10
Reblozyl Generic name: luspatercept Drug class: miscellaneous erythropoiesis agents	4 reviews	10 / 10
Revlimid Generic name: lenalidomide Drug class: miscellaneous antineoplastics, other immunosuppressants	22 reviews	7.2 / 10
Reyataz Generic name: atazanavir Drug class: protease inhibitors	4 reviews	8.8 / 10
Sotyktu Generic name: deucravacitinib Drug class: multikinase inhibitors	7 reviews	5.1 / 10
Sprycel Generic name: dasatinib Drug class: BCR-ABL tyrosine kinase inhibitors	21 reviews	7.5 / 10
Sustiva Generic name: efavirenz Drug class: NNRTIs	6 reviews	5.2 / 10
Thalomid Generic name: thalidomide Drug class: leprostatics, miscellaneous antineoplastics, other immunosuppressants
Vidaza Generic name: azacitidine Drug class: miscellaneous antineoplastics	14 reviews	5.9 / 10
Yervoy Generic name: ipilimumab Drug class: anti-CTLA-4 monoclonal antibodies	2 reviews	9.5 / 10
Zeposia Generic name: ozanimod Drug class: selective immunosuppressants	5 reviews	8.0 / 10
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).